1. Asset and indication
The drug or program, the disease or use you care about, and any scope that must stay in or out (line of therapy, population, geography).
Briefing
Start with the asset.
Tell us the drug you care about. If you already have a disease in mind, we write a brief. If you need to see where it has been studied, that is Asset Scout. Either way, this is a real look — not a tour.
What to include
2. The decision
In-license, out-license, diligence, internal portfolio, or a specific go / no-go. We write to that question. We do not send a ranked list of ideas.
3. Constraints
Timing, confidentiality, and what you already believe. Customer materials stay customer materials.
